Benign Prostatic Hyperplasia Treatment Market by Therapeutic Class (5-Alpha Reductase Inhibitor, Alpha-Blocker, Phosphodiesterase-5 Inhibitor), Therapy (Combination Drug Therapy, Mono Drug Therapy), End User - Global Forecast 2023-2030

Benign Prostatic Hyperplasia Treatment Market by Therapeutic Class (5-Alpha Reductase Inhibitor, Alpha-Blocker, Phosphodiesterase-5 Inhibitor), Therapy (Combination Drug Therapy, Mono Drug Therapy), End User - Global Forecast 2023-2030


The Benign Prostatic Hyperplasia Treatment Market is projected to reach USD 13.76 billion by 2030 from USD 8.03 billion in 2022, at a CAGR of 6.96% during the forecast period.

Market Segmentation & Coverage:

This research report analyzes various sub-markets, forecasts revenues, and examines emerging trends in each category to provide a comprehensive outlook on the Benign Prostatic Hyperplasia Treatment Market.
  • Based on Therapeutic Class, market is studied across 5-Alpha Reductase Inhibitor, Alpha-Blocker, and Phosphodiesterase-5 Inhibitor. The Phosphodiesterase-5 Inhibitor is projected to witness significant market share during forecast period.
  • Based on Therapy, market is studied across Combination Drug Therapy and Mono Drug Therapy. The Combination Drug Therapy is projected to witness significant market share during forecast period.
  • Based on End User, market is studied across Ambulatory Surgical Centers, Hospitals, and Specialty Clinics. The Ambulatory Surgical Centers is projected to witness significant market share during forecast period.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.75% in 2022, followed by Europe, Middle East & Africa.
Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is an indispensable tool for assessing the Benign Prostatic Hyperplasia Treatment Market. It comprehensively evaluates vendors, analyzing key metrics related to Business Strategy and Product Satisfaction. This enables users to make informed decisions tailored to their specific needs. Through advanced analysis, vendors are categorized into four distinct quadrants, each representing a different level of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V). Be assured that this insightful framework empowers decision-makers to navigate the market with confidence.

Market Share Analysis:

The Market Share Analysis offers invaluable insights into the vendor landscape Benign Prostatic Hyperplasia Treatment Market. By evaluating their impact on overall revenue, customer base, and other key metrics, we provide companies with a comprehensive understanding of their performance and the competitive environment they confront. This analysis also uncovers the level of competition in terms of market share acquisition, fragmentation, dominance, and industry consolidation during the study period.

Key Company Profiles:

The report delves into recent significant developments in the Benign Prostatic Hyperplasia Treatment Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Asahi Kasei Corporation, Astellas Pharma Inc., Boehringer Ingelheim GmbH, Boston Scientific Corporation, Eli Lilly and Company, Endo International PLC, GlaxoSmithKline plc, Merck KGaA, Mylan N.V., Pfizer, Inc., Sanofi S.A., Teleflex Incorporated, and Teva Pharmaceutical Industries Ltd..

The report offers valuable insights on the following aspects:
  1. Market Penetration: It provides comprehensive information about key players' market dynamics and offerings.
  2. Market Development: In-depth analysis of emerging markets and penetration across mature market segments, highlighting lucrative opportunities.
  3. Market Diversification: Detailed information about new product launches, untapped geographies, recent developments, and investments.
  4. Competitive Assessment & Intelligence: Exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of leading players.
  5. Product Development & Innovation: Intelligent insights on future technologies, R&D activities, and breakthrough product developments.
The report addresses key questions such as:
  1. What is the market size and forecast for the Benign Prostatic Hyperplasia Treatment Market?
  2. Which products, segments, applications, and areas hold the highest investment potential in the Benign Prostatic Hyperplasia Treatment Market?
  3. What is the competitive strategic window for identifying opportunities in the Benign Prostatic Hyperplasia Treatment Market?
  4. What are the latest technology trends and regulatory frameworks in the Benign Prostatic Hyperplasia Treatment Market?
  5. What is the market share of the leading vendors in the Benign Prostatic Hyperplasia Treatment Market?
  6. Which modes and strategic moves are suitable for entering the Benign Prostatic Hyperplasia Treatment Market?


Note: PDF & Excel + Online Access - 1 Year


1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Benign Prostatic Hyperplasia Treatment Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growth in cases of benign prostatic hyperplasia
5.1.1.2. Favorable reimbursement for surgeries and drug and treatemnt approvals
5.1.1.3. Government investments in improving healthcare infrastructure
5.1.2. Restraints
5.1.2.1. Side-effects related to BPH treatment
5.1.3. Opportunities
5.1.3.1. Emergence of minimally invasive treatments for benign prostatic hyperplasia
5.1.3.2. Ongoing research & development regarding benign prostatic hyperplasia
5.1.4. Challenges
5.1.4.1. Lack of efficacy of treatments
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of COVID-19
5.5. Cumulative Impact of Russia-Ukraine Conflict
5.6. Cumulative Impact of High Inflation
5.7. Porter’s Five Forces Analysis
5.7.1. Threat of New Entrants
5.7.2. Threat of Substitutes
5.7.3. Bargaining Power of Customers
5.7.4. Bargaining Power of Suppliers
5.7.5. Industry Rivalry
5.8. Value Chain & Critical Path Analysis
5.9. Regulatory Framework
5.10. Client Customization
6. Benign Prostatic Hyperplasia Treatment Market, by Therapeutic Class
6.1. Introduction
6.2. 5-Alpha Reductase Inhibitor
6.3. Alpha-Blocker
6.4. Phosphodiesterase-5 Inhibitor
7. Benign Prostatic Hyperplasia Treatment Market, by Therapy
7.1. Introduction
7.2. Combination Drug Therapy
7.3. Mono Drug Therapy
8. Benign Prostatic Hyperplasia Treatment Market, by End User
8.1. Introduction
8.2. Ambulatory Surgical Centers
8.3. Hospitals
8.4. Specialty Clinics
9. Americas Benign Prostatic Hyperplasia Treatment Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Benign Prostatic Hyperplasia Treatment Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Benign Prostatic Hyperplasia Treatment Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player
13. Competitive Portfolio
13.1. Key Company Profiles
13.1.1. Abbott Laboratories
13.1.2. AbbVie Inc.
13.1.3. Asahi Kasei Corporation
13.1.4. Astellas Pharma Inc.
13.1.5. Boehringer Ingelheim GmbH
13.1.6. Boston Scientific Corporation
13.1.7. Eli Lilly and Company
13.1.8. Endo International PLC
13.1.9. GlaxoSmithKline plc
13.1.10. Merck KGaA
13.1.11. Mylan N.V.
13.1.12. Pfizer, Inc.
13.1.13. Sanofi S.A.
13.1.14. Teleflex Incorporated
13.1.15. Teva Pharmaceutical Industries Ltd.
13.2. Key Product Portfolio
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings